# EDGAR Filing Document

**Accession Number:** 0002123975
**File Stem:** 0002123975-26-000006
**Filing Date:** 2026-5
**Character Count:** 10690
**Document Hash:** 22847901d2df05b8383606d4f05561cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002123975-26-000006.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0002123975-26-000006

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioNTech SE
- **CENTRAL INDEX KEY:** 0001776985
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91373
- **FILM NUMBER:** 26986901

**BUSINESS ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131
- **BUSINESS PHONE:** 0049613190840

**MAIL ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sahin Ugur
- **CENTRAL INDEX KEY:** 0002123975

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 55131

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Issuer:** BioNTech SE

**Title of Class of Securities:** Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 03/31/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Medine GmbH | Names of Reporting Persons<br>Medine GmbH |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>2M | Citizenship or Place of Organization<br>2M |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>39218111.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>39111390.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>39218111.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>39218111.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>15.5% | Percent of Class Represented by Amount in Row (9)<br>15.5% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Item 9: Consists of 39,111,390 ordinary shares held by Medine GmbH and 106,721 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares.

---

| 1. | Names of Reporting Persons<br>Ugur Sahin | Names of Reporting Persons<br>Ugur Sahin |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>W8 | Citizenship or Place of Organization<br>W8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>858209.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>39218111.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>858209.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>39111390.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>40076320.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>40076320.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>15.8% | Percent of Class Represented by Amount in Row (9)<br>15.8% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Item 6: Consists of 39,111,390 ordinary shares held by Medine GmbH, 858,209 ordinary shares held by Prof. Ugur Sahin, M.D., and 106,721 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares.

---

**Item 1(a). Name of Issuer:**
BioNTech SE

**Item 1(b). Address of Issuer's Principal Executive Offices:**
An der Goldgrube 12, Mainz, Germany, 55131

**Item 2(a). Name of Person Filing:**
This Amendment No. 6 to Schedule 13G is being jointly filed by Medine GmbH and Prof. Ugur Sahin, M.D., each of the foregoing, a "Reporting Person," and together, the "Reporting Persons".

The Reporting Persons have entered into a Joint Filing Agreement, dated February 13, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 13, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of each of the Reporting Persons is Philipp-von-Zabern-Platz 1, D-55116 Mainz, Germany.

**Item 2(c). Citizenship:**
Medine GmbH is a German limited liability company (Gesellschaft mit beschrankter Haftung). Prof. Ugur Sahin, M.D. is a citizen of Turkey.

**Item 2(d). Title of Class of Securities:**
Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See the responses to Item 9 on the attached cover pages.

**(b) Percent of class:**

See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See the responses to Item 5 on the attached cover pages.

**(ii) Shared power to vote or to direct the vote:**

See the responses to Item 6 on the attached cover pages.

**(iii) Sole power to dispose or to direct the disposition of:**

See the responses to Item 7 on the attached cover pages.

**(iv) Shared power to dispose or to direct the disposition of:**

See the responses to Item 8 on the attached cover pages.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

See responses to Item 2(a) and Item 4.

**Item 7. Identification and Classification of the Subsidiary**

See responses to Item 2(a) and Item 4.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Medine GmbH**

**Date:** 05/15/2026

**By:** /s/ Prof. Ugur Sahin, M.D.

**Name & Title:** Prof. Ugur Sahin, M.D./Authorized Signatory

**Ugur Sahin**

**Date:** 05/15/2026

**By:** /s/ Prof. Ugur Sahin, M.D.

**Name & Title:** Prof. Ugur Sahin, M.D.